Simon Allen, M.B.A., served as our Chief Business Officer from September 2010 to January 2015 and from March 2019 to the present. Mr. Allen established multiple partnerships for Ambrx with companies such as BMS, Pfizer, Merck, Eli Lilly, Astellas, ZMC, Beigene and SinoBiopharma that have generated over $270 million in revenue to date and have the potential to generate an additional $1 billion in future milestones plus royalties on product sales.
Prior to rejoining the company in 2018, Mr. Allen was Chief Executive Officer of CohBar from March 2016 to December 2018 where he transitioned the company from the preclinical to clinical stage, listed the company on NASDAQ and qualified it for inclusion into the Russell 2000 index. In the past, Mr. Allen held various management and business development positions within the biopharma industry at companies such as Nuvelo, Skyepharma, CovX and Kalypsys. Mr. Allen started his career as a research biologist in the antiviral group at Gilead Sciences before working as a healthcare analyst in the financial sector.
Mr. Allen holds a B.Sc. degree in biochemistry and genetics from the University of Sydney and an M.B.A. from the Australian Graduate School of Management.